EF
BPMC

Empirical Finance’s Blueprint Medicines BPMC Stock Holding History

Empirical Finance’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,708
Closed -$365K – 471
2022
Q1 		$365K Hold
5,708
– – 0.04% 375
2021
Q4 		$611K Sell
5,708
-4,243
-43% -$444K 0.07% 252
2021
Q3 		$1.02M Hold
9,951
– – 0.15% 136
2021
Q2 		$875K Buy
+9,951
New +$912K 0.14% 168

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Empirical Finance's BPMC Position: Q2 2022 in Review

Empirical Finance sold out of Blueprint Medicines (BPMC) in Q2 2022, closing a stake of 5,708 shares — an estimated $365K sold.

Empirical Finance first reported a position in BPMC in Q2 2021 and held it in 4 quarters. The position peaked at $1.02M in Q3 2021. 237 funds tracked by Wall St. Rank hold BPMC as of Q2 2022.

  • Empirical Finance reported no remaining Blueprint Medicines position as of Q2 2022 after selling out during the quarter.
  • Empirical Finance sold 5,708 Blueprint Medicines shares in Q2 2022, an estimated $365K.
  • Empirical Finance first reported a position in Blueprint Medicines in Q2 2021 and held it in 4 quarters.
  • Empirical Finance's Blueprint Medicines position peaked at $1.02M in Q3 2021.
  • 237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2022.

Based on Empirical Finance's 13F filing for Q2 2022, filed 1 Aug 2022.